1. Medtech Insight
  2. >>Business
  3. >>Strategy

COVID-19 Medtech Lessons: Data Point To ‘Healthy Industry In An Unhealthy Time’ But Business Models Must Change

 
• By Phil Greenfield

Ernst &Young’s annual Pulse of the Industry report says strong R&D spending by medtechs in 2019 bodes well for their post-pandemic recovery as industry leaders point to long-term changes to the industry that companies must navigate when future-proofing their business models.

Telescope

Medtech companies looking to recover from the challenges of the global pandemic now face likely permanent changes to their business models, including supply chain management, collaborations, health care delivery, and digitalization as they futureproof operations against future disruption and plan effective deployment of limited capital resources.

This was one of the main conclusions of a 6 October industry leader panel at the recent AdvaMed Virtual Medtech Conference, launching EY’s 14th annual

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.

More from Business